INM004
Hemolytic uremic syndrome (Shiga toxin‑producing E. coli)
Phase 3Active
Key Facts
Indication
Hemolytic uremic syndrome (Shiga toxin‑producing E. coli)
Phase
Phase 3
Status
Active
Company
About Inmunova
Argentinian biotech developing a first‑in‑class anti‑Shiga toxin therapy for HUS.
View full company profile